Vanguard Group Inc. trimmed its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 0.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,184,289 shares of the biotechnology company's stock after selling 44,766 shares during the period. Vanguard Group Inc. owned about 9.74% of Arrowhead Pharmaceuticals worth $229,065,000 as of its most recent SEC filing.
A number of other institutional investors also recently modified their holdings of ARWR. R Squared Ltd bought a new position in Arrowhead Pharmaceuticals during the 4th quarter valued at approximately $38,000. Van ECK Associates Corp raised its holdings in shares of Arrowhead Pharmaceuticals by 72.3% during the fourth quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company's stock valued at $56,000 after acquiring an additional 1,250 shares in the last quarter. KBC Group NV lifted its stake in Arrowhead Pharmaceuticals by 45.9% in the fourth quarter. KBC Group NV now owns 5,224 shares of the biotechnology company's stock worth $98,000 after acquiring an additional 1,644 shares during the period. Envestnet Portfolio Solutions Inc. bought a new stake in Arrowhead Pharmaceuticals in the fourth quarter valued at $190,000. Finally, First Citizens Bank & Trust Co. purchased a new position in Arrowhead Pharmaceuticals during the 4th quarter valued at $205,000. 62.61% of the stock is currently owned by hedge funds and other institutional investors.
Arrowhead Pharmaceuticals Stock Down 5.8 %
Shares of NASDAQ:ARWR traded down $0.69 on Thursday, hitting $11.11. 2,743,380 shares of the company traded hands, compared to its average volume of 1,403,016. The stock has a 50 day simple moving average of $16.23 and a 200-day simple moving average of $18.91. The company has a quick ratio of 6.09, a current ratio of 6.09 and a debt-to-equity ratio of 7.27. The company has a market cap of $1.53 billion, a PE ratio of -2.15 and a beta of 0.99. Arrowhead Pharmaceuticals, Inc. has a 52 week low of $9.57 and a 52 week high of $30.41.
Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.97). As a group, research analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.
Analyst Ratings Changes
Several equities research analysts have recently commented on the stock. B. Riley reaffirmed a "buy" rating and issued a $38.00 target price (down from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, February 14th. Chardan Capital restated a "buy" rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. HC Wainwright reiterated a "buy" rating and set a $80.00 target price on shares of Arrowhead Pharmaceuticals in a report on Wednesday, February 12th. StockNews.com upgraded Arrowhead Pharmaceuticals to a "sell" rating in a research note on Friday, December 20th. Finally, Royal Bank of Canada restated an "outperform" rating and set a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, Arrowhead Pharmaceuticals has a consensus rating of "Hold" and an average price target of $41.44.
View Our Latest Stock Report on ARWR
Insider Buying and Selling
In related news, CEO Christopher Richard Anzalone sold 51,425 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $15.07, for a total transaction of $774,974.75. Following the sale, the chief executive officer now directly owns 4,062,377 shares of the company's stock, valued at $61,220,021.39. This trade represents a 1.25 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders sold a total of 185,717 shares of company stock worth $3,064,441 in the last three months. Insiders own 4.30% of the company's stock.
About Arrowhead Pharmaceuticals
(
Free Report)
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.
Featured Stories
Before you consider Arrowhead Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list.
While Arrowhead Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
